Antiparkinsonian Agents, Anticholinergic Agents Flashcards
Increases the risk of psychosis
Effective in the urgent treatment of Neuroleptic malignant syndrome (NMS)
bromocriptine (Parlodel)
Used for: Dystonia, Parkinsonism, Akinesia, Akathisia
benztropine (Cogentin)
Cogentin
1-2 mg BID
PO/IM/IV
benztropine
__________ is responsible for:
S - salivation
L – lacrimation (tearing of the eyes)
U - urination
D - diarrhea
G – gastrointestinal motility
E - emesis
Acetylcholine
is a chronic progressive, degenerative disorder of the CNS
Symptoms:
resting tremor
bradykinesia
rigidity
postural instability
Risk Factors:
Age
Genetics
Sex
Exposure to Toxins
Parkinsons disease
Part of the Extrapyramidal Nervous System
Controls motor movement
Nigrostriatal pathway
Dopamine in Nigrostriatal pathway:
Decrease in Dopamine
Results in: __________
Parkinson Disease and EPS
Dopamine in Nigrostriatal pathway:
Chronic Blockage of D2 Receptors
Results in: __________
Hyperkinetic Movement Disorder (Tardive Dyskinesia)
______ of d2 receptors or ____ dopamine levels – difficulty controlling voluntary and involuntary muscle movement
Loss; low
___________ nervous system nerve fibres that are responsible brainstem to motor fibres of spinal cord (unconscious, reflexive or responsive control of musculature – muscle tone, balance, posture, locomotion)
Extrapyramidal
There is a reciprocal relationship between __________ and _________
Dopamine; Acetylcholine
Normal Functioning = Dopamine controls ____________ release
acetylcholine
widening the blood vessels in the cardiovascular system allowing blood to flow more easily.
Vasodilator
Blocking Dopamine (=decrease d2) causes an increase in ______
Increasing d2=decrease in Ach
ACh
_____ – receptor sites found in NIGROSTRIATAL pathways, dicephalon, medulla
Also found in peripheral nervous system – (rest and digest – parasympathetic)
CNS
________ receptor sites – found in parasympathetic nervous system
Cholinergic
Increase in acetylcholine activity = increase in ___________ side effects (nigrostriatal pathway)
extrapyramidal
_________ acetylcholine activity by reducing Dopamine increases the risk of EPS
Increasing
_____ potency antipsychotics have a high risk of EPS because of potency of dopamine blocking – hence increase in acetylcholine release – lower risk of anticholinergic effects
High
______ potency antipsychotics have a lower risk of EPS because potency of dopamine blocking is not as high and therefore not as much acetylcholine is released - but a much higher risk of _________ effects
Low; anticholinergic
Increase dopamine activity in the brain
E.g. bromocriptine (Parlodel)
Dopamine Receptor Agonists